Collateral for a security interest recorded Dec 23, 2025 (JPMorgan Chase Bank, N.A.).
Term ended no later than May 17, 2026 · Medium confidence
20-year base term ended May 17, 2026
Held by Bausch + Lomb Ireland Limited
Filed Feb 16, 2012 as application 13/398,542 · Granted Nov 26, 2013
Base term, 20 years from filing
Today
Ended no later than May 17, 2026
2006
2026
Clock starts
May 17, 2006
May 17, 2006
Ended no later than
May 17, 2026
May 17, 2026
Granted
Nov 26, 2013
Nov 26, 2013
base term
after the term ends
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
Unresolved
Terminal disclaimer
On file, reference document not resolved, so the date above is an upper bound. We do not guess the cap.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
35
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is on file with no resolved reference, so no cap is applied and none is guessed. All three maintenance fees were paid, so no fee lapse ended it. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts May 17, 2006, when application 11/436,906, the earliest non-provisional in its chain, was filed (this one was filed Feb 16, 2012) | May 17, 2026 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer on file (approved), reference document not resolved | no cap applied, and none guessed | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | term ended | High confidence |
| Computed term end | The steps above, in order | no later than May 17, 2026 | Medium confidence |
This family
| US 8,168,655 | In force May 2029 | May 2029 |
| Application 12/508,311 | Abandoned not computed | not computed |
| US 8,084,047 | Term ended May 2026 | May 2026 |
| US 8,771,715 | Term ended May 2026 | May 2026 |
| US 8,758,776 | Term ended Nov 2024 | Nov 2024 |
| US 8,592,450 | this patent no later than May 2026 | no later than May 2026 |
| Application 13/962,440 | Abandoned not computed | not computed |
| Application 13/962,369 | Abandoned not computed | not computed |
8 of 35 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Mar 8, 2012 Reel 27825, frame 955 | Gadek, Thomas; Burnier, John | Sarcode Bioscience Inc. | Assignment of Assignor's Interest |
| Mar 8, 2012 Reel 27831, frame 440 | Sarcode Corporation | Sarcode Bioscience Inc. | Assignment of Assignor's Interest |
| May 24, 2012 Reel 28266, frame 907 | Shen, Wang; Oslob, Johan D.; Barr, Kenneth; Zhong, Min | Sunesis Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| May 24, 2012 Reel 28267, frame 173 | Sunesis Pharmaceuticals, Inc. | Sarcode Bioscience Inc. | Assignment of Assignor's Interest |
| Feb 8, 2013 Reel 29778, frame 888 | Sarcode Bioscience Inc. | Silicon Valley Bank | Security Agreement |
| Feb 13, 2013 Reel 29804, frame 51 | Sarcode, A California Corporation | Sarcode Corporation, a Corporation of State of Delaware | Merger |
| Apr 25, 2013 Reel 30295, frame 28 | Silicon Valley Bank | Sarcode Bioscience Inc. | Release of Security Interest |
| Oct 31, 2019 Reel 50900, frame 268 | Sarcode Bioscience Inc. | Novartis AG | Assignment of Assignor's Interest |
| Oct 22, 2020 Reel 54134, frame 708 | Novartis AG | Novartis Pharmaceuticals Corporation | Assignment of Assignor's Interest |
| Jun 7, 2021 Reel 56497, frame 31 | Gadek, Thomas; Burnier, John | Sarcode Corporation | Corrective Assignment to Correct the Assignee Name and Address in Cover Sheet from Sarcode Bioscience Inc, to Sarcode Corporation Previously Recorded at Reel: 027825 Frame: 0955. Assignor(S) Hereby Confirms the Assignment. |
| Dec 6, 2023 Reel 65789, frame 853 | Novartis Pharmaceuticals Corporation | Bausch + Lomb Ireland Limited | Assignment of Assignor's Interest |
| Dec 23, 2025 Reel 74050, frame 573 | Bausch + Lomb Ireland Limited | JPMorgan Chase Bank, N.A., as Collateral Agent | Intellectual Property Security Agreement |
| Dec 23, 2025 Reel 74050, frame 709 | Bausch + Lomb Ireland Limited | Citibank, N.A., as Notes Collateral Agent | Intellectual Property Security Agreement |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Note
A terminal disclaimer is on file and its reference is not resolved. No cap is applied and none is guessed
Open question
A terminal disclaimer is on file (approved) and its reference document is not resolved. A disclaimer would cap the term earlier than May 17, 2026. We will not guess the cap.
Citations
34
later US patents cite this one
That is top 25% of utility patents granted in 2013 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
This computed term ends no later than the date shown; an unresolved terminal disclaimer may end it earlier. Related patents and pending applications may cover overlapping subject matter.